Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course

Journal of Chemotherapy
M Socan

Abstract

The efficacy of a 5-day regimen consisting of 500 mg in a single dose on the first day followed by 250 mg once daily for 4 consecutive days was compared with that of a 3-day course of azithromycin given in single daily doses of 500 mg for treatment of atypical pneumonia. Adult patients hospitalized with atypical pneumonia in the years 1990 to 1993 were studied retrospectively. For each patient, the medical history, laboratory data, the results of serological tests, chest radiographs and treatment outcome were reviewed. Out of 148 patients with atypical pneumonia, 40 were treated with azithromycin for 5 days (Group 1) and 41 for 3 days (Group 2). The success rate in Group 1 was 80% (32 patients). Eight patients did not respond to treatment: 5 had significant complement fixing antibody titers to adenovirus and in 3 the etiology was unknown. The success rate in Group 2 was 88% (36 patients). Azithromycin was ineffective in all 3 patients with adenoviral pneumonia, in 1 patient with Q fever, and in 1 patient with no identified pathogen. Azithromycin is equally effective as treatment of atypical pneumonia in adult patients if given for 3 or 5 days at the same total dose.

References

Oct 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D L MorrisW E Morgan
Oct 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G Kinasewitz, R G Wood
Sep 1, 1991·The Journal of Antimicrobial Chemotherapy·A Pérez-del-MolinoJ Gonzalez-Macias
Nov 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H Renaudin, C Bébéar
Dec 14, 1995·The New England Journal of Medicine·J G Bartlett, L M Mundy
Dec 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·T J Marrie

❮ Previous
Next ❯

Citations

May 4, 2004·Current Medical Research and Opinion·Lala M DunbarAlan M Tennenberg
Mar 18, 2006·International Journal of Antimicrobial Agents·Michael S Niederman
Nov 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas M File
Sep 7, 2018·The Cochrane Database of Systematic Reviews·Jesús López-AlcaldeManuel Gómez-García
May 15, 2007·Current Opinion in Infectious Diseases·Nikole M Scalera, Thomas M File
Aug 10, 2010·American Journal of Respiratory and Critical Care Medicine·Grant W WatererRichard G Wunderink
Feb 19, 2015·Current Opinion in Infectious Diseases·Stefano AlibertiUNKNOWN DURATION Study Group
Nov 28, 2007·Expert Review of Anti-infective Therapy·Silvano Esposito, Marco Fiore
Apr 25, 2019·Environmental Research·Suraj PanthiAmir Sapkota
Sep 2, 2020·European Journal of Medicinal Chemistry·Anton Firth, Praveen Prathapan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses
M GoyetteF Corbeil
The Journal of the American Dental Association
S L BrooksS K Young
© 2022 Meta ULC. All rights reserved